Market Cap | 19.97M | P/E | - | EPS this Y | 58.20% | Ern Qtrly Grth | - |
Income | -28.19M | Forward P/E | -0.74 | EPS next Y | 5.10% | 50D Avg Chg | -34.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
Dividend | N/A | Price/Book | 0.58 | EPS next 5Y | - | 52W High Chg | -52.00% |
Recommedations | 1.70 | Quick Ratio | 3.25 | Shares Outstanding | 30.88M | 52W Low Chg | 49.00% |
Insider Own | 18.06% | ROA | -65.99% | Shares Float | 23.67M | Beta | 1.18 |
Inst Own | 36.16% | ROE | -142.45% | Shares Shorted/Prior | 402.97K/404.15K | Price | 0.94 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 87,761 | Target Price | 7.00 |
Oper. Margin | - | Earnings Date | Nov 12 | Volume | 163,146 | Change | -7.84% |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Cantor Fitzgerald | Overweight | Apr 9, 24 |
Cantor Fitzgerald | Overweight | Apr 1, 24 |
Cantor Fitzgerald | Overweight | Sep 7, 23 |
Chardan Capital | Buy | Nov 17, 22 |
SVB Leerink | Outperform | Aug 12, 22 |
Cantor Fitzgerald | Overweight | Jun 8, 22 |
B. Riley Securities | Buy | Jun 7, 22 |
Chardan Capital | Buy | Jun 7, 22 |
SVB Leerink | Outperform | Jun 7, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Hamdy Ahmed MD | See Remarks See Remarks | Aug 09 | Buy | 0.95 | 22,300 | 21,185 | 96,060 | 08/10/23 |
THOMAS TOM C | See Remarks See Remarks | Aug 10 | Buy | 0.95 | 5,000 | 4,750 | 219,935 | 08/10/23 |
Izumi Raquel E. | See Remarks See Remarks | Aug 09 | Buy | 0.92 | 16,476 | 15,158 | 85,214 | 08/10/23 |
Izumi Raquel E. | See Remarks See Remarks | Dec 14 | Buy | 0.8848 | 28,738 | 25,427 | 68,738 | 12/14/22 |
Hamdy Ahmed MD | Chief Executive Offi.. Chief Executive Officer | Dec 14 | Buy | 0.8656 | 35,280 | 30,538 | 73,760 | 12/14/22 |
THOMAS TOM C | See Remarks See Remarks | Dec 14 | Buy | 0.83 | 7,000 | 5,810 | 10,000 | 12/14/22 |
Hamdy Ahmed MD | Chief Executive Offi.. Chief Executive Officer | Jun 23 | Buy | 1.4106 | 24,200 | 34,137 | 38,480 | 06/27/22 |
Bushnell Laura I. | Director Director | Jun 09 | Buy | 1.9083 | 15,000 | 28,624 | 19,202 | 06/13/22 |